FUJIFILM Diosynth Biotechnologies Opens New Laboratory Facility in Research Triangle Park, NC
MORRISVILLE, N.C., May 9, 2016 – FUJIFILM Diosynth Biotechnologies U.S.A., Inc., a Biologics Contract Development and Manufacturing Organization with experience focused on the development and manufacture of recombinant biopharmaceuticals including proteins, vaccines, and monoclonal antibodies, completed the construction of a new three-story, 62,000 square foot state-of-the-art facility in Research Triangle Park, North Carolina. A ribbon cutting ceremony was held on May 9th, 2016. Members of the local government and biotech community were in attendance at the event.
“The construction and completion of this building reflects the continued commitment of our organization to provide our clients with the infrastructure to efficiently and innovatively bring their products to the clinic and beyond for the benefit of their patients,” said Steve Bagshaw, CEO, FUJIFILM Diosynth Biotechnologies.
The new building, called BioProcess Innovation Center, houses the company’s Process and Analytical Research and Development, Process Sciences and Stability groups. These will concentrate on delivering excellence in process invention, design and development and process and product characterization for our clients. They will also continue to innovate to further develop systems and approaches which rapidly lead to efficient, robust and high quality biomanufacturing processes.
“The design of the facility reflects our core philosophy of cross-functional collaboration to Research and Process Development which is a key differentiator of our company,” said Martin Meeson, President, FUJIFILM Diosynth Biotechnologies U.S.A., Inc. “Developer Alexandria Real Estate Equities, Inc., and General Contractor, KBR Building Group, LLC, brought a wealth of experience in life science building projects to this new addition to FUJIFILM Diosynth Biotechnologies, located at 6051 George Watts Hill Drive.”
FUJIFILM Diosynth Biotechnologies U.S.A., Inc. is an industry-leading Biologics Contract Development and Manufacturing Organization located in Research Triangle Park, North Carolina. FUJIFILM Diosynth has over thirty years of combined experience in the development and manufacturing of recombinant proteins, vaccines, monoclonal antibodies, among other large molecules expressed in a wide array of microbial, mammalian, and insect cell line systems. The company offers a comprehensive list of services from cell line development using its proprietary pAVEway™ microbial and Apollo™ cell line systems to process development, analytical development, clinical and FDA-approved commercial manufacturing. FUJIFILM Diosynth Biotechnologies is also located in Billingham, UK as FUJIFILM Diosynth Biotechnologies UK Limited and in College Station, Texas as FUJIFILM Diosynth Biotechnologies Texas, LLC. For more information, go to: fujidio.sp-stage1.emagineusa.net
FUJIFILM Holdings Corporation, Tokyo, Japan brings continuous innovation and leading-edge products to a broad spectrum of industries, including: healthcare, with medical systems, pharmaceuticals and cosmetics; graphic systems; highly functional materials, such as flat panel display materials; optical devices, such as broadcast and cinema lenses; digital imaging; and document products. These are based on a vast portfolio of chemical, mechanical, optical, electronic, software and production technologies. In the year ended March 31, 2014, the company had global revenues of $23.9 billion, at an exchange rate of 102 yen to the dollar. Fujifilm is committed to environmental stewardship and good corporate citizenship. For more information, please visit: www.fujifilmholdings.com.
All product and company names herein may be trademarks of their registered owners.